Researchers 'turn off' most notorious cancer-causing protein

December 2, 2015, University of Toronto
Researchers ‘turn off’ most notorious cancer-causing protein
Mouse tumour

It's known as the most common cancer-causing protein, directly responsible for 30 per cent of all cancers and indirectly involved in virtually all cancers. For over 30 years, scientists have failed to successfully target it, but now researchers from U of T can turn this protein off with an experimental drug.

"For several decades, scientists have tried to turn off a protein called Ras," said Michael Ohh, a professor in the Faculty of Medicine's Department of Laboratory Medicine and Pathobiology. "But despite their efforts, we ultimately haven't seen much progress. In fact, it's been coined the 'undruggable' protein."

Normally, Ras promotes cell growth, but it can also cause when mutated or deregulated. As a result, this protein is a key player in many forms of and is mutated in over 90 per cent of pancreatic tumours—one of the deadliest forms of cancer.

The discovered that another protein, called SHP2, turns Ras off. "Our lab is known for another area of cancer biology. But on the request from a colleague, we entered the Ras field about five years ago to study mutations in a rare form of childhood leukemia," said Ohh. "We were surprised to find that nobody had identified SHP2 as a switch that regulates Ras that it could be targeted."

Working with researchers from Indiana University and Toronto's University Health Network, the team tested a SHP2 inhibitor on mice with glioblastoma, the most common and aggressive type of brain cancer. Remarkably, the inhibitor reduced these tumours by over 80 per cent.

"The inhibitors' results were incredible—we were shocked," said Ohh. "Nothing has had the same effect."

The researchers' findings were recently published in Nature Communications.

Dr. Yoshihito Kano (left) and Professor Michael Ohh

Next, the team will work with a cancer surgeon at the University of North Carolina to treat mice that have human pancreatic tumours. If the SHP2 inhibitor is effective, the

researchers will use this evidence to support future human clinical trials.

"In addition to being a researcher, I'm also a gastroenterologist and I see a lot of patients with ," said Yoshihito Kano, co-author of the publication along with Severa Bunda, the primary author. "These patients usually die within one year, even with chemotherapy, so this drug could potentially change my patients' lives."

While their research is still in its early stages, Ohh and his team hope that their discovery will open up new perspectives in the field and potentially change cancer treatment.

"By better understanding how this cancer-causing works, we hope to target it much more precisely than before," said Ohh. "At the end of the day, we want other researchers to build on our fundamental discovery, providing more options for patients."

Explore further: Mouse study suggests genomic screening before cancer treatment may prevent anemia

More information: Severa Bunda et al. Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis, Nature Communications (2015). DOI: 10.1038/ncomms9859

Related Stories

Mouse study suggests genomic screening before cancer treatment may prevent anemia

October 13, 2015
Many types of leukemia are caused by loss of enzymes such as Pten, which normally keeps cell growth in check, or conversely, the over-activation of enzymes that normally enhance cell proliferation, such as Shp2. Some anti-leukemia ...

Bacterial sepsis protein may inhibit cancer cell growth

June 8, 2015
A toxin secreted by Vibrio vulnificus, a water and food-borne bacteria that can cause rapidly lethal infections in persons with liver disease, has potential to prevent the growth of tumors, according to a new study by Northwestern ...

Combining the old and new to kill cancer cells

March 23, 2015
A team of Singapore based scientists have found that pairing a new approach with an old drug may be an effective approach to treat common cancers. In a landmark study, Professor David Virshup and Dr. Jit Kong Cheong, from ...

Scientists uncover potential drug to tackle 'undruggable' fault in third of cancers

November 4, 2014
Scientists have found a possible way to halt one of the most common faults in many types of cancer, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool today.

A newly discovered tumor suppressor gene affects melanoma survival

November 2, 2015
Of the hundreds of genes that can be mutated in a single case of melanoma, only a handful may be true "drivers" of cancer. In research that appeared last week in Nature Genetics, a Weizmann Institute of Science team has now ...

Blocking 'lock and key' site of lung cancer proteins could lead to new treatments

November 12, 2013
A Cancer Research UK study reveals that stopping two essential lung cancer proteins from joining together at their 'lock and key' site could lead to new treatments for the disease. The research is published in the journal ...

Recommended for you

Researchers discover novel mechanism linking changes in mitochondria to cancer cell death

February 20, 2018
To stop the spread of cancer, cancer cells must die. Unfortunately, many types of cancer cells seem to use innate mechanisms that block cancer cell death, therefore allowing the cancer to metastasize. While seeking to further ...

Stem cell vaccine immunizes lab mice against multiple cancers

February 15, 2018
Stanford University researchers report that injecting mice with inactivated induced pluripotent stem cells (iPSCs) launched a strong immune response against breast, lung, and skin cancers. The vaccine also prevented relapses ...

Induced pluripotent stem cells could serve as cancer vaccine, researchers say

February 15, 2018
Induced pluripotent stem cells, or iPS cells, are a keystone of regenerative medicine. Outside the body, they can be coaxed to become many different types of cells and tissues that can help repair damage due to trauma or ...

Team paves the way to the use of immunotherapy to treat aggressive colon tumors

February 15, 2018
In a short space of time, immunotherapy against cancer cells has become a powerful approach to treat cancers such as melanoma and lung cancer. However, to date, most colon tumours appeared to be unresponsive to this kind ...

Can our genes help predict how women respond to ovarian cancer treatment?

February 15, 2018
Research has identified gene variants that play a significant role in how women with ovarian cancer process chemotherapy.

First comparison of common breast cancer tests finds varied accuracy of predictions

February 15, 2018
Commercially-available prognostic breast cancer tests show significant variation in their abilities to predict disease recurrence, according to a study led by Queen Mary University of London of nearly 800 postmenopausal women.

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

betterexists
1 / 5 (1) Dec 02, 2015
Now, New Major Pathway to No Cancer Humans Opens up!
Just Don't Return back; NEVER!
big_hairy_jimbo
5 / 5 (2) Dec 02, 2015
Incredible. This should be fast tracked for Humans with Pancreatic and Brain Cancer. If your prognosis is poor, what do you have to lose by being involved in a trial. I know I would certainly sign ALL consent forms to be a guinea pig, should I be given a cancer death sentence.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.